Selling Your Veterinary Practice to Blue River PetCare: A 2026 Guide

Key takeaways

• Blue River PetCare is a Chicago-based, Partners Group-backed veterinary practice consolidator founded in 2009 — operating more than 200 independently-branded general practice hospitals across the US per Blue River company materials.
• The defining feature is a decentralized model: each acquired practice retains full clinical autonomy — protocols, drug choices, vendors, software — and keeps its existing name and brand identity. Blue River provides back-office infrastructure, not clinical direction.
• Partners Group has backed Blue River since a significant equity investment in July 2019. In late 2024, Blue River appointed Leerink Partners to explore a potential sale; any resulting ownership change would require verification against a formal press release before relying on it in a transaction.
• Blue River does not publish a standard price sheet. The specific offer for any practice depends on profile, geography, and — most critically — whether other qualified buyers are underwriting the same practice in parallel.
• The most reliable way to know what Blue River — or any major buyer — would actually pay for your specific practice is a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. Blue River is invited inside that rope on practices that fit their criteria.

Most Blue River PetCare conversations I walk into with a practice owner start the same way. The owner has already had a call with someone from the Blue River team, and they’re sitting with a warm impression and a lot of unanswered questions.

The warm impression is understandable. Blue River’s people are good at what they do, and the pitch — autonomy, no rebrand, hands-off management — lands well with independent practice owners who have spent decades building something of their own.

The questions are where I earn my keep.

What follows is the same picture I’d lay out over dinner if a vet asked me what to do with a Blue River approach. Who they are, how their model actually works, where the negotiation leverage sits in 2026, and how to think about Blue River against the rest of the major buyer pool in a properly run process.

What is Blue River PetCare?

Blue River PetCare is a Chicago-based, Partners Group-backed veterinary practice consolidator that has operated with a decentralized, autonomy-first integration philosophy since its founding in 2009. The platform now includes more than 200 independently-branded general practice hospitals across the United States per Blue River company materials, making it one of the larger independent GP-focused consolidators in the US market.

Blue River was founded by Dan Blumenthal, Roy Jain, and Ferdie Schmitz — three executives who previously worked together at Willis Stein & Partners, a Chicago private equity firm, where they were involved in building National Veterinary Associates during its growth phase. Blumenthal serves as CEO.

The founders built Blue River on a deliberate thesis: that the veterinary M&A landscape was moving too fast toward integration-heavy models that standardized away everything that made an independent practice distinctive, and that a buyer who preserved clinical identity and local brand would attract a different — and better — quality of seller.

Blue River made its first acquisition in May 2010. Over the first 4 years, the platform added only 10 hospitals.

Growth accelerated materially after Partners Group’s July 2019 investment per the Partners Group press release at that time; Blue River reported 24% compound annualized revenue growth between 2019 and 2024, and expanded from roughly 90 hospitals across 23 states at the time of the 2019 investment to more than 200 locations today. At the time of the December 2024 reporting, Blue River generated approximately $100 million in adjusted EBITDA — a figure that reflects the platform’s substantial organic growth since the Partners Group investment.

On ownership in 2026: Partners Group made a significant equity investment in July 2019, with Blue River’s founders retaining a sizeable equity stake alongside that investment. In late 2024, per reporting from ION Analytics and Mergermarket, Blue River appointed Leerink Partners to explore a potential sale; bids reportedly came in at 15 to 16 times EBITDA with the platform targeting 17 to 19 times EBITDA.

As of the information available to us, no completed ownership change has been formally confirmed via press release. Verify current ownership status via Blue River’s official communications before closing any transaction.

What Blue River’s decentralized model means for selling vets in 2026

Blue River’s decentralized model is the through-line of every conversation. Each practice in the network maintains full clinical autonomy — protocols, drug choices, vendors, and software choices stay with the clinical team post-sale per Blue River company materials.

This is not a marketing phrase Blue River uses loosely. The platform’s integration architecture is built around it.

Back-office support — accounting, HR, payroll, marketing infrastructure, recruiting, professional development — flows in from the Blue River corporate team. Medicine, protocols, and patient care decisions stay with the doctors at the practice level.

The two systems run in parallel, intentionally separated.

For sellers evaluating what life looks like after the sale, the question is not whether Blue River means what they say about autonomy. The testimonials from practices that have joined the network are consistent on this point: “we have autonomy in the things we do, the decisions we make at the local level” per medical directors quoted in Blue River’s published testimonials.

The question is how the autonomy language gets written into the definitive agreement — because what matters at year 3 is what the purchase agreement says, not what was discussed over the first visit.

Per Blue River company materials, the no-rebrand commitment is explicit: practices do not get renamed, signage does not change, and local identity is preserved indefinitely. This contrasts with the integration model used by Mars-affiliated entities — VCA, Banfield, BluePearl — where acquired practices more commonly transition to a Mars-network brand over time per Mars company disclosures. Blue River and Mars operate on opposite ends of the integration spectrum, which matters to sellers for whom practice identity and community legacy are part of what they’re protecting in the sale.

How does Blue River PetCare structure its 2026 deals?

Blue River does not publish a standard price sheet for practice acquisitions. Each offer is customized to the individual practice’s profile per Blue River company materials, and negotiated case by case under confidentiality.

Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range — that is, the multiple applied to normalized EBITDA — across the major buyer pool when a structured competitive process is in place. Normalized EBITDA, for context, means the practice’s operating profit after adding back personal expenses the owner runs through the practice — vehicles, above-market owner compensation, family members on payroll at above-market rates — that a buyer will add back when valuing the practice.

Blue River’s specific offer structure includes a purchase price, transaction structure, facility lease terms, and post-transaction compensation per their acquisition process materials. The company describes its approach as customized — tailored to the individual owner’s goals — rather than a formulaic template.

For sellers whose primary goal is a clean exit without retained complexity, Blue River’s model tends to skew toward simpler structures; for sellers who want to retain a meaningful equity stake in the platform’s upside, the specific rollover mechanics would need to be negotiated explicitly, as Blue River’s standard posture is not publicly documented on this point.

What I consistently see in any process where Blue River competes against other qualified buyers: the offer that arrives through a single-bidder conversation reflects the leverage that buyer perceives in the room. No structural reason exists for any buyer — Blue River included — to lead with their strongest cash percentage, tightest earnout protections, and most flexible clinical-autonomy language when there’s no competitive pressure to do so. The number that comes out of a properly structured competitive process, where Blue River and 4 to 6 other qualified buyers are underwriting the same practice in parallel, is reliably a different number than what arrives in a direct, one-on-one outreach conversation.

How does Blue River compare to other major 2026 buyers?

If you’re considering a Blue River offer or approach, you’re likely comparing it — at least implicitly — to other buyers who would compete for your practice. Here’s how Blue River sits across the dimensions that matter.

Buyer	Ownership type	Brand handling	Clinical autonomy model	Primary practice focus
Blue River PetCare	PE-backed (Partners Group)	No rebrand; full local identity	Full clinical autonomy per company materials	GP companion animal
NVA	PE-backed (JAB Holdings, long-hold)	Local brand preserved	Local autonomy per company materials	GP and specialty
VetCor	PE-backed (Harvest Partners)	No rebrand; local identity	Local autonomy per company materials	GP and specialty
Mission Pet Health	PE-backed	Partnership model emphasis	Varies by deal structure	Sun Belt/Southeast GP
Mars (VCA/Banfield)	Strategic (family-owned)	Brand transition common	Centralized clinical standards	GP and specialty
AmeriVet	PE-backed	No rebrand	Partnership structure emphasis	GP

Versus NVA (JAB Holdings). NVA is owned by JAB Holdings, a long-hold investment vehicle with a different fund-cycle structure than a standard PE firm. Both NVA and Blue River emphasize local brand preservation per their respective company materials.

The key structural difference is fund ownership horizon — JAB’s long-hold posture creates different rollover-equity timing dynamics than a PE-fund-cycle owner like Partners Group. Our NVA buyer profile walks through the NVA-specific dimensions.

Versus VetCor (Harvest Partners). VetCor has more than two decades of integration history, which makes it the most tenured GP-focused consolidator in the US. Blue River’s operating record is shorter but its growth trajectory since 2019 is steep.

Both emphasize local brand preservation and clinical autonomy per their respective materials. Our VetCor buyer profile covers the VetCor-specific dimensions.

Versus Mission Pet Health. Mission Pet Health (the post-2025 entity formed from SVP and MVP per Mission Pet Health company communications) has emphasized partnership/joint-venture structures — buyer takes a majority stake, seller retains a minority with a defined exit window. Blue River’s standard posture leans toward conventional acquisition.

If retaining an equity stake in a partnership structure matters to you, Mission is worth comparing explicitly. Our Mission Pet Health buyer profile covers the partnership-model dimensions.

Versus Mars Veterinary Health (VCA, Banfield, BluePearl). Mars is the strategic family-owned exception in the major buyer pool per Mars company disclosures, not PE-backed. The brand-handling difference between Mars and Blue River is significant — Blue River’s no-rebrand model contrasts with VCA’s historical brand-transition approach under the VCA name.

For sellers where practice name continuity matters, that distinction shapes how the two buyers sit in a comparison. Our Mars buyer profile covers the Mars-specific dimensions.

Versus smaller PE-backed groups. Thrive Pet Healthcare, Alliance Animal Health, and others have their own integration philosophies and target profiles. Newer or smaller buyers sometimes pay more aggressively for practices that fill specific geographic or strategic gaps.

The right way to evaluate who pays most is to put the relevant buyers in a competitive process and let them surface their best offers in parallel. Our veterinary practice consolidators guide covers the broader landscape.

Who does Blue River PetCare acquire in 2026?

Blue River focuses on general practice companion-animal veterinary hospitals per Blue River company materials. The platform does not publicly enumerate a minimum revenue threshold, but the growth trajectory — from 90 hospitals at the 2019 Partners Group investment to 200-plus today — suggests an active acquisition appetite across multiple US markets and practice sizes.

At the time of the 2019 Partners Group investment, Blue River was operating across 23 US states, indicating broad geographic appetite rather than regional density concentration. That footprint has expanded since.

For practices at or above $2 million in revenue with 2 or more doctors, Blue River has historically been a serious bidder. The platform’s decentralized model scales well with multi-doctor practices that already have strong clinical teams and don’t need the acquirer to import operational expertise — they just need the back-office infrastructure freed up so the doctors can focus on medicine.

For single-doctor or sub-$1 million revenue practices, the buyer pool tends to shift toward smaller regional consolidators and individual buyers. Blue River’s institutional infrastructure and geographic scale are most relevant to practices large enough to benefit from centralized back-office support without the overhead becoming disproportionate.

For specialty or emergency hospitals, Blue River’s historical focus has been on general practice. Specialty-focused buyers (Ethos, BluePearl) have different underwriting criteria and pricing frameworks for specialty and ER platforms.

General practice is where Blue River’s model and experience sit.

Internal links for deeper context: our valuation guide walks through how normalized EBITDA gets calculated, and our PE pricing guide covers the 2026 multiple environment across the major buyer pool.

Where is the veterinary M&A market in 2026?

The broader US veterinary M&A market entered 2026 with a healthy rebound in deal activity per Capstone Partners‘ April 2026 Pet Sector M&A Update, which documents “an uptick of merger and acquisition activity through year-to-date 2026, as transactions delayed in 2025 have started to materialize and buyer appetite has experienced a healthy rebound.”

The same Capstone report identifies a structural factor relevant to Blue River’s ownership situation: financial sponsors formed 66 platforms between 2019 and 2022, and those portfolio companies are now at or beyond their prime harvest years. Capstone anticipates “a stronger pipeline of PE-backed assets to come to market in 2026 due to the fundamental structure of fund lifecycles, LP demand for distributions, and an improving exit environment.” Blue River fits squarely in that dynamic — Partners Group’s 2019 investment puts the platform in its seventh year, which is inside the typical 5-to-10-year PE hold cycle.

For sellers evaluating whether 2026 is the right moment to run a process: the current environment is active. Buyer appetite is strong, and platform-level PE exits are driving established buyers to bid aggressively to build scale before their own exit windows open. That competitive pressure benefits sellers who run a properly structured process rather than accepting a direct, single-bidder offer.

For more context on the current environment, our who to sell your veterinary practice to guide covers buyer-type selection across the 2026 landscape, and our earnout and rollover equity guide covers deal structure nuances in detail.

What to negotiate before signing with Blue River PetCare

Six priorities when the conversation with Blue River’s acquisition team gets to terms. The autonomy-protection provisions are the highest-leverage category given the platform’s decentralized philosophy — that philosophy needs to be in the contract, not just in the conversation.

Clinical autonomy language (highest priority). Blue River’s decentralized model is the platform’s most compelling feature for sellers who built their practices around a specific clinical culture. Get it in the definitive agreement explicitly.

The language should specify: you retain authority over clinical protocols; drug and vendor choices stay with the clinical team; Blue River provides back-office support but does not direct clinical decisions. Verbal commitment from the acquisition team is not the same as written agreement in the purchase documents.

Cash at close percentage. Push for the highest guaranteed cash percentage on the acquired stake. Every dollar shifted from contingent (earnout) to cash at close is guaranteed money rather than conditional on future performance.

Blue River’s model skews toward simpler deal structures, which is a reasonable starting point for the conversation. In a competitive process, the cash percentage can move.

Earnout protective provisions. If any portion of the deal value is structured as an earnout — paid after closing contingent on performance targets — negotiate protective provisions around it: no major operational changes during the earnout window without seller consent; working capital floor; clear definition of what counts in the EBITDA calculation at the earnout measurement date; prohibition on shifting central back-office costs to the practice during the earnout period.

Non-compete scope and duration. Non-competes typically run several years and cover a defined geographic radius for all veterinary work. Negotiate: shorter duration (1 to 2 years), tighter radius (5 to 10 miles), and explicit carve-outs if you plan to continue any specific modality or specialty work after the non-compete term ends.

Brand preservation in writing. Blue River’s no-rebrand commitment is central to their model. Get it in the agreement with teeth: the practice retains its current name, signage, and marketing identity unless the seller chooses otherwise; any name or brand change requires seller consent during the post-sale employment period.

Post-sale employment structure. Negotiate base salary, production bonus formula, and the clinical-autonomy language in the employment agreement alongside the purchase agreement. The employment agreement is where the day-to-day post-sale experience is actually governed — it deserves as much attention as the purchase price.

For a broader look at what moves the number in a competitive process, our sell my veterinary practice guide covers the full sale preparation and process framework.

What do I actually do when Blue River PetCare reaches out?

The consistent pattern across Blue River conversations. When Blue River’s acquisition team makes initial contact with a practice owner, the owner typically has a positive first impression and a lot of open questions about what comes next.

The answer to “what comes next” is not “respond to Blue River and move toward a deal.” The answer is: get into a position where you understand what your practice is worth to the full buyer pool, not just to Blue River.

Blue River is one buyer. The US veterinary buyer pool includes dozens of active, qualified acquirers — PE-backed groups, specialty-focused platforms, long-hold investment vehicles, and strategic buyers — each of whom will underwrite your practice differently based on their own portfolio needs, geographic priorities, and fund timing.

The number Blue River tables in a single-bidder conversation reflects what they believe they need to table to get the deal done. The number they table when they know other qualified buyers are in the room is a different number.

Running a structured competitive process — our Elite Selling System — is how sellers consistently clear meaningfully more than the initial direct offer, and how the deal terms (cash percentage, earnout protections, clinical-autonomy language, brand commitments) get to a place that’s actually written into the documents rather than promised in conversation.

If a Blue River approach is in front of you right now, the right first call is not to Blue River’s team. It’s to us.

Get a Free Blue River PetCare Offer Review →

Send us the offer or the term sheet and we’ll decompose every element: purchase price, cash at close percentage, earnout structure, employment terms, non-compete, and brand-handling language. We’ll project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool — and what the gap between that number and the direct offer actually looks like in dollars.

No upfront cost, no obligation. We only get paid when a deal closes, and only out of value created above what you would have realized on your own.

---

Frequently asked questions

What is Blue River PetCare?

Blue River PetCare is a Chicago-based, Partners Group-backed veterinary practice consolidator founded in 2009 by former private equity professionals Dan Blumenthal, Roy Jain, and Ferdie Schmitz. The platform operates more than 200 independently-branded general practice hospitals across the United States per Blue River company materials.

Its defining feature is a decentralized model: each acquired practice retains full medical autonomy — including protocols, drug choices, and vendors — along with its local name and brand identity.

Who owns Blue River PetCare?

Blue River PetCare is backed by Partners Group, a Swiss-based global private equity firm. Partners Group made a significant equity investment in Blue River in July 2019 per a Partners Group press release at that time, with Blue River’s founders retaining a sizeable equity stake alongside the Partners Group investment.

Note: In late 2024, Blue River appointed Leerink Partners to explore a potential sale; any resulting ownership change would be announced via formal press release.

Does Blue River PetCare rebrand acquired veterinary practices?

Per Blue River company materials, Blue River does not rebrand or change the culture of practices that join its network. Each practice retains its original name, signage, and local identity following acquisition.

The integration focuses on back-office support — accounting, HR, payroll, marketing, recruiting — rather than brand consolidation. This is one of the most consistently cited features in testimonials from veterinarians who have sold to Blue River per their published testimonials.

How much does Blue River PetCare pay for veterinary practices in 2026?

Blue River PetCare does not publish a standard price sheet. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

Blue River’s specific offer for any given practice is negotiated case by case under confidentiality and depends heavily on practice profile and whether a competitive process is in place.

What does Blue River PetCare’s decentralized model mean for selling vets in 2026?

Blue River’s decentralized model means each practice in the network maintains full clinical autonomy post-sale per Blue River company materials. The selling doctor retains authority over protocols, drug choices, vendors, and patient care decisions.

Blue River provides back-office infrastructure — accounting, HR, payroll, marketing, recruiting — while leaving medicine to the clinicians. Practices keep their existing name and community brand identity.

What type of veterinary practices does Blue River PetCare acquire?

Blue River PetCare focuses on general practice companion-animal veterinary hospitals per Blue River company materials. The platform has historically targeted established multi-doctor practices with demonstrated revenue and growth potential.

At the time of Partners Group’s 2019 investment, Blue River was present across 23 US states, indicating broad geographic appetite for well-run practices across diverse markets rather than regional density concentration.

Is Blue River PetCare a good buyer for my veterinary practice?

Blue River PetCare is among the active US veterinary practice acquirers in 2026 and a serious bidder for practices that fit its general practice, multi-doctor profile. Its decentralized, autonomy-preserving model and no-rebrand approach are consistently cited as distinguishing features by practices that have joined the network per Blue River testimonials.

As with any major acquirer, Blue River is best evaluated head-to-head against other qualified buyers in a competitive process where each bidder underwrites the same practice in parallel.

What should I negotiate when selling to Blue River PetCare in 2026?

The highest-leverage negotiation points with Blue River PetCare include: cash at close percentage (push for maximum guaranteed cash versus contingent earnout); earnout protective provisions (definitions, working capital floor, no cost-shifting during the earnout window); post-sale clinical autonomy language (explicit written commitment to the decentralized model); non-compete duration and radius; and post-sale compensation structure including base salary and production bonus formula.

---

Sources

Industry M&A research and valuation data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. ION Analytics / Mergermarket. “Blue River PetCare launches sale process, sources say.” December 2024. ionanalytics.com
3. ION Analytics / Mergermarket. “Blue River PetCare appoints Leerink Partners to explore sale.” July 2024. ionanalytics.com
4. CARE for Pets. “Large Veterinary Consolidator Reportedly Launches Sale Process.” December 2024. pets.care

Public company disclosures and PE filings

5. Partners Group. “Partners Group to invest in Blue River PetCare, a leading US operator of veterinary hospitals.” Press release, July 2, 2019. partnersgroup.com

Specific buyer corporate materials

6. Blue River PetCare. “Our Difference.” blueriverpetcare.com
7. Blue River PetCare. “Practice Owners.” blueriverpetcare.com
8. Blue River PetCare. “Our Veterinary Acquisition Process.” blueriverpetcare.com
9. Blue River PetCare. “Testimonials.” blueriverpetcare.com
10. Blue River PetCare. “Ditching a Dog-Eat-Dog Approach: A Look at Consolidating with Care.” blueriverpetcare.com